All In Biotech

Drug Trial Radar · NCT03089944

A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis

A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis

Last checked: Nov 20, 2026Latest source record: Jul 13, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

343

Actual

Start

Apr 28, 2017

Primary completion

Jul 31, 2019

Study completion Nov 8, 2019

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Mar 24, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 3b, single arm, open-label, multicenter study in treatment naïve adults with chronic HCV infection and compensated cirrhosis to assess the safety of 8 weeks of treatment with glecaprevir/pibrentasvir and to demonstrate the efficacy of the sustained virologic response 12 weeks post dosing (SVR12) rates of 8 weeks of treatment with glecaprevir/pibrentasvir compared to the historical SVR12 rates of 12 weeks of treatment with glecaprevir/pibrentasvir.

Conditions

  • Hepatitis C Virus (HCV)

Interventions

  • Glecaprevir/PibrentasvirDrug

    Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Hepatitis C Virus (HCV) Genotype (GT) 1,2,4,5 and 6-infected Participants in the Per Protocol (PP) PopulationTime frame: 12 weeks after last dose of study drug
  2. Percentage of Participants With SVR12 in HCV GT 1,2,4,5 and 6-infected Participants in the Intent-To-Treat (ITT) PopulationTime frame: 12 weeks after last dose of study drug

Locations

113 sites in 19 countries. Site status is shown where the registry gives one.

  • St. Josephs Hosp and Med Ctr /ID# 162762

    Phoenix, Arizona

  • Mayo Clinic Arizona /ID# 162314

    Phoenix, Arizona

  • Liver Wellness Center /ID# 162244

    Little Rock, Arkansas

  • Felizarta /ID# 162295

    Bakersfield, California

  • VA Long Beach Healthcare System /ID# 162298

    Long Beach, California

  • Usc /Id# 162248

    Los Angeles, California

  • Kaiser Permanente - San Diego (Palm Ave) /ID# 162289

    San Diego, California

  • Stanford University School of Med /ID# 162209

    Stanford, California

  • Cedars-Sinai Medical Center - West Hollywood /ID# 162313

    West Hollywood, California

  • University of Miami /ID# 162210

    Miami, Florida

  • Triple O Research Institute /ID# 162300

    West Palm Beach, Florida

  • Piedmont Hospital /ID# 162646

    Atlanta, Georgia

  • Northwestern University Feinberg School of Medicine /ID# 162208

    Chicago, Illinois

  • Unity Point Health /ID# 162247

    Des Moines, Iowa

  • The University of Iowa Hospita /ID# 162214

    Iowa City, Iowa

  • University of Louisville /ID# 162242

    Louisville, Kentucky

  • Louisiana Research Ctr. LLC /ID# 162567

    Shreveport, Louisiana

  • Mercy Medical Center /ID# 162291

    Baltimore, Maryland

  • Mayo Clinic - Rochester /ID# 162251

    Rochester, Minnesota

  • Southern Therapy and Advanced Research (STAR) LLC /ID# 162241

    Jackson, Mississippi

  • CHI Health Alegent Creighton /ID# 162286

    Omaha, Nebraska

  • Univ Nebraska Med Ctr /ID# 162285

    Omaha, Nebraska

  • Rnjms /Id# 162213

    Newark, New Jersey

  • Weill Cornell Medical College /ID# 161051

    New York, New York

  • Icahn School of Med Mt. Sinai /ID# 162294

    New York, New York

  • Montefiore Medical Center /ID# 162312

    The Bronx, New York

  • James J. Peters VA Medical Center /ID# 162644

    The Bronx, New York

  • Duke University Medical Center /ID# 162299

    Durham, North Carolina

  • Cumberland Research Assoc /ID# 162212

    Fayetteville, North Carolina

  • Carolinas Center for Liver Dis /ID# 162569

    Statesville, North Carolina

  • University Hospitals Cleveland /ID# 162243

    Cleveland, Ohio

  • Cleveland Clinic /ID# 162570

    Cleveland, Ohio

  • Osuchs /Id# 162284

    Tulsa, Oklahoma

  • Lehigh Valley Health Network /ID# 162603

    Allentown, Pennsylvania

  • Center for Liver Diseases, Oakland /ID# 162568

    Pittsburgh, Pennsylvania

  • Vanderbilt Univ Med Ctr /ID# 162211

    Nashville, Tennessee

  • Texas Digestive Disease Consul /ID# 162648

    Dallas, Texas

  • University of Texas Health /ID# 162288

    Houston, Texas

  • Virginia Commonwealth Univ /ID# 162215

    Richmond, Virginia

  • Univ of Wisconsin Hosp/Clinics /ID# 162645

    Madison, Wisconsin

Showing 40 of 113 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.